ForSight VISION5 Inc. CEO John Maroney discussed his company’s novel, non-invasive insert system, Helios. Placed on the surface of the eye, under the eyelid, Helios enables glaucoma and ocular hypertensive patients to continually receive medication (such as “the drug of choice” prostaglandin A), eliminating their need to regularly administer eye drops. Results from a Phase II US study of Helios for glaucoma should be available by the end of the year.
John Maroney is CEO of ForSight VISION5. John was a full-time member of the Delphi Ventures investment team for over ten years, where he focused on early stage medical device investments and continues his board of directors relationship with one of the Delphi Ventures portfolio companies.